Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial

This publication has 19 references indexed in Scilit:

• Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid
  The Lancet, 1999
• The Incidence of False-Positive Cultures for Mycobacterium Tuberculosis
  American Journal of Respiratory and Critical Care Medicine, 1997
• Treatment of Tuberculosis and Tuberculosis Infection in Adults and Children. American Thoracic Society and the Centers for Disease Control and Prevention
  American Journal of Respiratory and Critical Care Medicine, 1994
• The Effect of Directly Observed Therapy on the Rates of Drug Resistance and Relapse in Tuberculosis
  New England Journal of Medicine, 1994
• Effectiveness of Rifampin, Rifabutin, and Rifapentine for Preventive Therapy of Tuberculosis in Mice
  American Review of Respiratory Disease, 1993
• Assessment of New Sterilizing Drugs for Treating Pulmonary Tuberculosis by Culture at 2 Months
  American Review of Respiratory Disease, 1993
• A 62-Dose, 6-Month Therapy for Pulmonary and Extrapulmonary Tuberculosis
  Annals of Internal Medicine, 1990
• USPHS Tuberculosis Short-Course Chemotherapy Trial 21: Effectiveness, Toxicity, and Acceptability
  Annals of Internal Medicine, 1990
• In vitro properties of rifapentine (MDL473) relevant to its use in intermittent chemotherapy of tuberculosis
  Tubercle, 1987
• Kinetic Studies on Rifampicin
  Chemotherapy, 1971